09/08/2026 US FDA Fast Track Designation for FAP‑targeted radionuclide conjugate GPN01530-2 US FDA Fast Track Designation for FAP‑targeted radionuclide conjugate GPN01530-2 (Ref) Grand Pharmaceutical Group Limited announced that its investigational radionuclide-drug conjugate GPN01530-2, targeting fibroblast activating protein (FAP), has received Fast Track Designation from the US FDA